AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 26 min read$TEM

Tempus AI Revenue Up 23%; Gains Cut Net Loss: Rapid Earnings Reaction

Tempus AI reported a 23% revenue increase to $411.5M in Q3, with Data and Applications revenue up 33%. The net loss narrowed to $14.9M, though operating loss remained high. Adjusted EBITDA rose to $25.6M. The company raised its 2026 revenue outlook, and shares rose 3.9% in pre-market trading.

Original reporting
finance.yahoo.com
Published Nov 2, 2026, 4:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 4:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Tempus AI Revenue Up 23%; Gains Cut Net Loss: Rapid Earnings Reaction — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$TEMBullishMed
01

Why it matters

The key tradable tension is growth and gross margin strength versus the quality of earnings and dilution from stock-based compensation, with guidance raising revenue but not adjusted EBITDA.

02

Market read

Fresh quarterly numbers and guidance can drive positioning, but the market may discount non-operating gains and scrutinize operating progress and EBITDA delivery.

03

What to watch

Adjusted EBITDA outlook is said to hold around $65M, so traders should focus on whether Q4 EBITDA reaches the implied level and whether hereditary testing revenue re-accelerates.

Relevance 9/10Novelty 8/10Timing: pre-market today, immediately after the earnings release

Background

The article frames Tempus AI’s Q3 as a mix of strong revenue growth and margin improvement in Data and Applications, alongside persistent operating losses.

Company-level read

Ticker impact

$TEMBullishHigh confidence
Context

Tempus AI reported Q3 revenue up 23% to $411.5M, narrowed net loss, and raised its 2026 revenue outlook, with pre-market shares up ~3.9%.

Expected impact

Likely near-term support as investors price in stronger top-line growth, with follow-through dependent on whether adjusted EBITDA guidance is met.

Evidence & confidence

The piece contains fresh quarterly results plus an updated 2026 revenue outlook and discusses the quality of earnings (non-operating unrealized gains vs operating loss).

Market effects

Sector

Signals improving unit economics in AI data/testing services, but highlights that stock-based pay and non-operating gains can distort headline losses.

Regional

Limited, company-specific US growth story for AI healthcare data analytics.

Global

Low; no cross-border policy or global macro linkage beyond general AI healthcare sentiment.

Counterpoint

What could challenge this read

Treat the net-loss narrowing cautiously because the article attributes most improvement to unrealized marketable-securities gains that can reverse.

Key entities

  • company
    Tempus AI

    NASDAQ-listed AI healthcare data and testing company reporting Q3 results and updated 2026 revenue outlook.

Read at source← All news

StoryTempus AI posts record Q3 revenue, first adjusted profit and raises full‑year outlook

Also covered by

6 outlets

Related articles

NOV 3
$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

investing.com2 min
NOV 3
$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.

finance.yahoo.com2 min
NOV 2
$TEMMedAI 8/10

Tempus AI (TEM): Oncology Volume Surge and Data Licensing Bookings Signal a Profitable Inflection

Tempus AI (TEM) reported Q3 2026 revenue of $411.5M, up 23% YoY, with adjusted EBITDA of $25.6M. Oncology revenue grew 28% to $172.6M, while Data and Applications revenue increased 33% to $108.1M. The company raised full-year revenue guidance to $1.60B-$1.605B and expects near-term catalysts from reimbursement improvements and the pending $1.7B Personalis acquisition.

news.alphastreet.com7 min